权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE

俄亥俄州立大学和 MD 安德森癌症中心甲状腺癌孢子

基本信息

批准号：
8548721
负责人：
Matthew D Ringel
金额：
$ 215.05万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-25 至 2018-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8548721
关键词：
Accounting Address Adverse effects Area Behavior Biological Biological Assay Biological Markers Biological Process Biostatistics Core Budgets Cancer Center Cancer Detection Cancer Patient Cancer Survivor Candidate Disease Gene Case-Control Studies Cells Cessation of life Clinical Management Clinical Research Clinical Trials Collaborations Combined Modality Therapy Complication Continuance of life Critiques Cyclin-Dependent Kinases DNA Dental Detection Development Diagnosis Disease Disease Outcome Distant Metastasis Doctor of Medicine Drug resistance Early Diagnosis Functional disorder Genes Genetic Goals Incidence Individual Indolent Institution Intervention Knowledge Life Long Term Survivorship MEKs Malignant Neoplasms Malignant neoplasm of thyroid Measures Molecular Abnormality Monitor Mutation Neoplasm Circulating Cells Neoplasm Metastasis Ohio Outcome Pain Papillary thyroid carcinoma Partial Remission Pathway interactions Patients Penetrance Phase II Clinical Trials Play Population Predisposition Preventive Property Prospective Studies Proteomics Publishing Quality of life Radioactive Iodine Recommendation Recording of previous events Recurrence Reporting Reproduction spores Research Research Personnel Resistance Risk Role Salivary Glands Stable Disease TNFRSF5 gene Taste Perception Testing Therapeutic Transcript Translational Research Translational Research Working Group Translations United States Universities University of Texas M D Anderson Cancer Center Untranslated RNA Validation Vertebrates Woman Xerostomia base cancer risk cancer stem cell career career development clinical care clinical practice experience genome wide association study human subject protection improved in vivo inhibitor/antagonist medullary thyroid carcinoma meetings men mortality novel novel strategies patient population prevent programs response survivorship tumor tumor progression

项目摘要

DESCRIPTION 3 OVERALL CRITIQUE 3 SPORE PROGRAM ORGANIZATION AND CAPABILITIES 6 SCIENTIFIC COLLABORATIONS 8 PROTECTION OF HUMAN SUBJECTS 10 VERTEBRATE ANIMALS 10 SCIENTIFIC REVIEW OFFICER'S NOTES 10 INDIVIDUAL PROJECTS AND CORES 11 PROJECT 1: Low-Penetrance Genes in the Predispositon to Papillary Thyroid Cancer 11 PROJECT 2: Preserving Salivary Gland Function after Radioiodine Therapy for Thyroid Cancer 15 PROJECT 3: Developing Combination Therapies for Medullary Thyroid Cancer 23 PROJECT 4: Development and Validation of Novel Circulating Medullary Thyroid Cancer Markers 29 CORE A/1: Integrated Clinicopathology and Biorespository Core 34 CORE B/2: Biostatistics Core 38 CORE C/3: Administrative Core 41 DEVELOPMENTAL RESEARCH PROGRAM 43 CAREER DEVELOPMENT PROGRAM 45 COMMITTEE BUDGET RECOMMENDATIONS 48 SPECIAL EMPHASIS PANEL ROSTER DESCRIPTION (provided by applicant): The primary goal of The Ohio State University / M.D. Anderson Thyroid Cancer SPORE is to improve the outcomes and lives of patients with thyroid cancer by identifying genetically "at-risk" individuals allowing for early diagnosis and prediction of tumor behavior, developing new approaches to minimize side effects of treatments, and developing better biomarkers and treatment options for progressive metastatic disease. Several factors support the importance of applying these efforts to thyroid cancer: 1) Thyroid cancer incidence is rising at the fastest rate of all malignancies in the United States and worldwide; it s now the 5th most common malignancy in women and 11th most common in men. 2) Thyroid cancer typically takes an indolent course, thus with the increasing incidence there is an ever enlarging population of individuals (-500,000) surviving long term, many of whom suffer from lifelong effects of initial therapy. 3) For patients with more aggressive forms of thyroid cancer, such as medullary cancer (MTC), there exist no curative therapies or biomarkers that accurately predict outcome from disease or response to particular treatments thereby limiting efforts to individualize therapeutic intensity. In order to achieve our goals, this SPORE application proposes to support a multi-institutional team of experienced investigators from two of the leading institutions in the field with a history of collaborative clinical trials. We have chosen t focus on critical areas of need for rapid translation into clinical practice for thyroid cancer patients with the following four Projects supported by outstanding Cores: 1) Low-penetrance genes in the predisposition to papillary thyroid carcinoma; 2) Biomarker discovery and personalized intervention of radioiodine induced salivary gland damage in thyroid cancer patients; 3) Developing combination therapies for Medullary Thyroid Cancer; and 4) Development and validation of novel circulating medullary thyroid cancer markers. Through these translational Projects, as well as Career Developmental and Developmental Research Programs, we aim to impact on critical areas of need in thyroid cancer clinical management for all forms of thyroid cancer. RELEVANCE: Thyroid cancer incidence is rising. Key issues in clinical care related to predictive testing for more aggressive disease, improving survivorship as many patients live for decades after their diagnosis, improving treatment for patients with aggressive forms of thyroid cancer and improving detection and monitoring of metastases This SPORE addresses these critical areas to improve the outcomes of patients with thyroid cancer.

描述3